NASDAQ:VIVO - Meridian Bioscience Stock Price, Forecast & News

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its quarterly earnings results on Friday, February, 7th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.04. The firm had revenue of $47.42 million for the quarter, compared to the consensus estimate of $48.71 million. Meridian Bioscience had a return on equity of 13.02% and a net margin of 9.70%. View Meridian Bioscience's Earnings History.

Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Meridian Bioscience.

Meridian Bioscience updated its FY 2020 Pre-Market earnings guidance on Friday, February, 7th. The company provided earnings per share guidance of 0.28-0.34 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.30. The company issued revenue guidance of $194.984-201.014 million, compared to the consensus revenue estimate of $198.54 million.

4 equities research analysts have issued 12 month target prices for Meridian Bioscience's stock. Their forecasts range from $8.00 to $14.00. On average, they expect Meridian Bioscience's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 39.2% from the stock's current price. View Analyst Price Targets for Meridian Bioscience.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Meridian Bioscience.

Press coverage about VIVO stock has trended somewhat positive on Monday, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Meridian Bioscience earned a news impact score of 1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Meridian Bioscience.

Some companies that are related to Meridian Bioscience include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), Anika Therapeutics (ANIK), Antares Pharma (ATRS) and OraSure Technologies (OSUR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), Cara Therapeutics (CARA), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Roku (ROKU), General Electric (GE), Procter & Gamble (PG), Advanced Micro Devices (AMD), Amgen (AMGN) and Exelixis (EXEL).

Meridian Bioscience's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (7.67%), State Street Corp (3.73%), Acadian Asset Management LLC (1.43%), Bank of New York Mellon Corp (1.30%), Assenagon Asset Management S.A. (1.20%) and Point72 Asset Management L.P. (1.20%). Company insiders that own Meridian Bioscience stock include David Phillips, Dwight E Ellingwood, James M Anderson, John Mccune Jr Rice, John Mcilwraith, John P Kenny and Lawrence Baldini. View Institutional Ownership Trends for Meridian Bioscience.

VIVO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., AJO LP, Oxford Asset Management LLP, New York State Common Retirement Fund, Charles Schwab Investment Management Inc., Martingale Asset Management L P, Royce & Associates LP and Bessemer Group Inc.. View Insider Buying and Selling for Meridian Bioscience.

VIVO stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Jacobs Levy Equity Management Inc., M&G Investment Management Ltd., Acadian Asset Management LLC, Assenagon Asset Management S.A., Russell Investments Group Ltd., AQR Capital Management LLC and Bank of Montreal Can. Company insiders that have bought Meridian Bioscience stock in the last two years include David Phillips, Dwight E Ellingwood, James M Anderson, John Mccune Jr Rice, John Mcilwraith and John P Kenny. View Insider Buying and Selling for Meridian Bioscience.

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VIVO stock can currently be purchased for approximately $7.90.

Meridian Bioscience has a market capitalization of $338.36 million and generates $201.01 million in revenue each year. The company earns $24.38 million in net income (profit) each year or $0.68 on an earnings per share basis. Meridian Bioscience employs 585 workers across the globe.View Additional Information About Meridian Bioscience.

The official website for Meridian Bioscience is http://www.meridianbioscience.com/.

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.